"Next-gen metabolic peptides" for aging: hype vs. actual data

What did @kristisawicki actually say?

The creator, who says she holds a PhD in molecular and cellular oncology, makes the case that two compounds she calls "reta" and "tris" are "next-gen metabolic signaling compounds" that "activate multiple pathways." She describes retatrutide as a GLP-3 analog that adds a glucagon receptor target to increase energy expenditure, and tirzepatide as the more established dual-agonist with longer data. She also claims both "lower risk of cardiovascular disease" through lipid profile changes and improve insulin sensitivity and liver function. The video is framed as educational, not medical advice, and promotes a downloadable "peptide cheat sheet."

It is worth being upfront: the compounds she is describing are not peptides in the clinical sense that most biohacking communities use the term. They are pharmaceutical drug candidates or approved drugs. Calling them "metabolic peptides" in a biohacking context significantly blurs that line.

Does the science back this up?

Partially, but with important caveats. Tirzepatide has real, peer-reviewed trial data. Retatrutide is still in Phase 2 trials. The creator is right about the mechanisms but overstates the certainty of outcomes, especially cardiovascular risk reduction.

Tirzepatide (brand name Mounjaro/Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist. The SURPASS trial program, published in the New England Journal of Medicine (Jastreboff et al., 2022), showed significant weight loss and glycemic improvements. The SURMOUNT-4 trial confirmed durability of these effects. Cardiovascular outcomes data from SURPASS-CVOT showed a 17% reduction in major adverse cardiovascular events, published in the New England Journal of Medicine (Bhatt et al., 2025). So the cardiovascular claim for tirzepatide has emerging support, though it is not yet the complete picture.

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023) showed up to 24% body weight reduction, which is notable. But Phase 3 data does not yet exist, and no cardiovascular outcomes trial has been completed. Calling it a proven cardiovascular risk reducer at this stage is getting ahead of the evidence.

What did they get wrong (or right)?

She gets the receptor pharmacology roughly right but overstates the evidence base, particularly for retatrutide. She also significantly undersells the risk profile of these compounds.

The description of retatrutide as targeting "the glucagon receptor" as an added mechanism on top of GLP-1 is mechanistically accurate. The claim that this "increases energy expenditure" is supported by preclinical and early clinical data (Jastreboff et al., 2023, NEJM). Credit where it is due.

However, several problems stand out:

• Saying both compounds "lower risk of cardiovascular disease" treats Phase 2 data and completed outcomes trials as equivalent. They are not.
• Framing these as "peptides" in a biohacking context creates a false equivalency with unregulated compounds like BPC-157 or CJC-1295. Tirzepatide is a regulated pharmaceutical. Retatrutide is an investigational drug not available outside clinical trials.
• There is no mention of side effects: nausea, vomiting, gastroparesis risk, potential thyroid C-cell concerns, or the fact that retatrutide is not legally available to consumers in any form.
• The "cheat sheet" promotional link at the end raises real questions about whether this is education or lead generation for a product or service.

What should you actually know?

These are not compounds you can simply obtain and self-administer. One is a regulated FDA-approved drug; the other is an investigational compound in trials. Neither belongs in a gray-market peptide stack.

Tirzepatide is available by prescription in the United States for type 2 diabetes and obesity. It has a real evidence base. But it also carries a black box warning for thyroid C-cell tumors based on animal data, and it requires medical supervision, dose titration, and monitoring. Compounded versions exist in some pharmacies under current FDA enforcement discretion, but compounded tirzepatide is not equivalent to brand-name Zepbound or Mounjaro, and patients should understand that distinction before using any compounded version.

Retatrutide is not approved. It is not legally available outside of clinical trials run by Eli Lilly. Any source selling or supplying it is operating outside regulatory frameworks. The Phase 2 data is promising, but promising Phase 2 results have failed to translate to approved drugs many times. Treating this compound as accessible or safe to use now is premature and potentially dangerous.

If metabolic health and healthy aging are your actual goals, the foundation remains what it has always been: resistance training, dietary quality, sleep, and when clinically indicated, working with a licensed provider to evaluate whether FDA-approved medications are appropriate for your situation.